

GENOMMA LAB INTERNACIONAL INFORMS INDEPENDENT EXTERNAL AUDITOR RATIFICATION

Mexico City, November 10, 2020 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that, through unanimous resolutions taken out of session of the Company’s Board of Directors, dated as of October 20, 2020, whereby, among other matters, Galaz, Yamazaki, Ruiz Urquiza, S.C. (“Deloitte”), was ratified as external auditor of the Company’s consolidated financial statements for the 2020 fiscal year.

Therefore, in compliance under article 17 of the “Circular Única de Auditores”, hereby submits certified copy by the Secretary non-member of the Board of Directors, concerning the resolution mentioned above by which the Company’s Board of Directors approves ratifying the appointment of Deloitte.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com

Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “**LABB**” (**Bloomberg: LABB:MM**).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company’s related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

EXTRACTO DE LAS RESOLUCIONES UNÁNIMES ADOPTADAS FUERA SESION POR LA TOTALIDAD DE LOS MIEMBROS DEL CONSEJO DE ADMINISTRACIÓN DE GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. ADOPTADAS EL 20 DE OCTUBRE DE 2020.

RESOLUCIÓN SEXTA

[...]

Adicionalmente, con la opinión favorable del Comité de Auditoría y Prácticas Societarias y con fundamento en lo dispuesto en el artículo 16 de las Disposiciones de carácter general aplicables a las entidades y emisoras supervisadas por la Comisión Nacional Bancaria y de Valores que contraten servicios de auditoría externa de estados financieros básicos, se aprueba:

- (i) La ratificación del despacho Galaz, Yamazaki, Ruiz Urquiza, S.C. (“Deloitte”) para que realice la auditoría de los estados financieros consolidados de la Sociedad correspondientes al ejercicio social 2020; y
- (ii) La ratificación y/o designación, según sea el caso, de los despachos externos mencionados en el “Anexo 1” de estas resoluciones, para que realicen la auditoría de los estados financieros individuales de las principales subsidiarias de la Sociedad que en dicho anexo se mencionan.

[...]

El suscrito, Secretario no miembro del Consejo de Administración de Genomma Lab Internacional, S.A.B. de C.V. (la “Sociedad”), hago constar que esta transcripción es un extracto fiel, en su parte conducente, de las resoluciones unánimes adoptadas fuera Sesión por la totalidad de los miembros del Consejo de Administración de la Sociedad adoptadas el 20 de octubre de 2020.

Ciudad de México, México, a 6 de noviembre de 2020.



Lic. Efraín Tapia Córdoba
Secretario no miembro del Consejo de Administración
Genomma Lab Internacional, S.A.B. de C.V.